Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (January 2024)
29 slides from Matinas Biopharma's investor presentation, Jan 9, 2024
Slide 1: Matinas BioPharma Corporate Presentation January 2024
MATINAS BIOPHARMA Corporate Presentation January 2024 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value Lipid Nanocrystals (LNCs) MAT2203 ~ a Less toxicity vVVVV Clinical Validation of LNC Capabilities Oral Amphotericin B - without nephrotoxicity Phase 3-ready (Invasive Aspergillosis in ~198 patients with limited or no treatment options
Slide 4: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Delivery of small molecules and small oligonucleotides hte. fe3 g si » Successful delivery of small molecules, proteins, small oligonucleotides (siRNA, ASOs), and vaccines Extra-hepatic targeting * Selective uptake dri
Slide 5: Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery Targeting Stressed Cells Externalize PS Normally, PS with injury, is confined to PS moves from the inner the inner layer layer to the outer layer (facing cytosol) of the cell membrane (CELL MEMBRANE 9 5. g28s PHOSPHATIDYLSERINE
Slide 6: MAT2203: Oral Amphotericin B
MAT2203 Oral Amphotericin B Clinical Validation of LNC Delivery MATINAS ‘BIOPHARMA
Slide 7: The Growing Threat of Invasive Fungal Infections (IFIs)
The Growing Threat of Invasive Fungal Infections (IFls) WIRED Nature Reviews Microbiology 2022 The Bate Against the Fung Apocalypse ls Mabon an WHO fungal priority pathogens list to guide research, development and health action Wall Street Journal Deadly Fungal Infections Confound Doctors—"It's Goin
Slide 8: MAT2203: Unlocking the Full Potential of Amphotericin B
MAT2203: Unlocking the Full Potential of Amphotericin B Innate Amphotericin B IV Amphotericin B — Characteristics Limitations = Oo POTENT - Only available through broad-spectrum fungicidal \V administration © © © Minimal drug-drug interactions Low propensity for resistance Active against susceptible
Slide 9: EnACT: Phase 2 Clinical Validation of Safety and Efficacy
EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity Exceeded the primary All patients completing No breakthrough Survival at Day 30, MAT2203 was safe and end
Slide 10: Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal
0 Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal Clinical Infectious Diseases Vg! a] h ivma Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial David R. Boulware,” Mucunguzi Atukunda,** Enock Kagimu,? Abdu K. Musubire,’ Andrew Akampurir
Slide 11: MAT2203 Expanded Access Program - Targeted Treatment of IFIs Throughout the Body
MAT2203 Expanded Access Program - Targeted Treatment of IFls Throughout the Body Sinus Mucor nidicola Pansinusitis Lung Aspergillus calidoustus Pulmonary aspergillosis Probable fusarium species Fusarium pneumonia Skin Prototheca wickerhamii Fusarium falciforme Skin infection Skin graft Fusarium spec
Slide 12: MAT2203 Expanded Access/Compassionate Use Program
MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options 14 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 — Notable Healthcare Institutions: NIH, University of Michigan,
Slide 13: Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203
Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203 MICHIGAN A 38 y/o female with systemic lupus erythematosus on chronic hydroxychloroquine and prednisone presented with a progressively enlarging wound on her left foot. = pre eters _ — ati arte net ena Pa matt pc owns c
Slide 14: High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)
High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA) * Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients = ~15,000 new cases per
Slide 15: MAT2203 Regulatory and Development Strategy
MAT2203 Regulatory and Development Strategy ¢ Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole) — Potential registrat
Slide 16: Proposed Phase 3 Study Design in Invasive Aspergillosis (IA)
Proposed Phase 3 Study Design in Invasive Aspergillosis (IA) » To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is superior to |V LAMB followed by SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive treatment with a mold-
Slide 17: MAT2203 Value Proposition
MAT2203 Value Proposition ORAL LACK OF AMPHOTERICIN B ADMINISTRATION ml NEPHROTOXICITY with a potent fungicidal age! LCM Treatment of Other IFIs > Prophylaxis (Proof enema) Near-Term Development Strategy: Focused strategy on Phase 3 registration trial in Invasive Aspergillosis in patients with limit
Slide 18: LNCs Beyond MAT2203
LNCs Beyond MAT2203 Efficient and Safe Delivery of Small Oligos MATINAS ~~ BIOPHARMA
Slide 19: LNC Therapeutic Cargo Experience to Date
9 LNC Therapeutic Cargo Experience to Date Infection Inflammation Animal model Jcoeo Cystic fibrosis mouse model ‘Amikacin ASO Indication [coro Mucocutaneous candidiasis Amphotericin - B Job's syndrome, NIH BALB/c mouse flu model Flu pre siRNA Vulvovaginal Candidiasis ee Amphotericin- B [Multiple mo
Slide 20: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Matinas is working internally and with third parties to broaden its pipeline of LNC-based therapeutics FUTURE I UNDER EVALUATION Potential Therapeutic Applications INFECTION » Anti-infectives © Antivirals *|NFLAMMATION PROVEN Oral Formulations Intrace
Slide 21: In vitro Tumor Cell Inhibition with LNC Docetaxel Formulations
/n vitro Tumor Cell Inhibition with LNC Docetaxel Formulations 3 LNC Formulations Demonstrated Significantly Better Tumor Cell Inhibition Than Unformulated Drug RATIONALE AND NEXT STEPS MMS1 -S-MMS3 -@-MM5S4 Taxol 8 * LNC Docetaxel program also provides insight into tumor uptake of LNCs — Foundation
Slide 22: In vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model
/n vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model Female C57BL/6 mice (0-40) ey 2000. 1500. 1000. 500 Tumor Volume (mm?) 2 10°B16F10 tumor cells Injection | a - Days $'Sr0UPS | yprate contol vith unre) Day14 count Doclae 0.15 me/mouse von dy and day 10 _ “en Or
Slide 23: LNC-formulated Small Oligos Show Strong Uptake in Innate Immune Cells
LNC-formulated Small Oligos Show Strong Uptake in Innate Immune Cells Support Role in Treating Inflammation 99.9 400 oie 945 81.6 80 g 70.8 € 63.1 § 5 6 3 ra 3 39.9 8 40 .) 4 8 20 é 38 ° 03 = 0.2 00 03 Neutrophils Monocytes moc pc 80 ug/mL LNC 512 ng/mL CyS-labeled siRNA cargo Hitimeo Gi 3hous GE 24
Slide 24: Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod (IMQ) Psoriasis Model
Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod (IMQ) Psoriasis Model Scaling 5 Groups * ‘ Day7 Naive g | *-p<0.001 047) g IMQ only : 2 INCE 1 9 yeymouse dey (ra gavage) 3 3 BalbC mice LNc2 £ FA (n= 50) IL47A murine Ab 1.mg/kgi.p. qod 3 af e s 2.0 7 5 7 Change in IL-17A Tissue mRNA at Day 7 van
Slide 25: Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model
Disease Activity Index Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model Groups Untreated control yr) DSS alone DSS + oral LNC 1 aren pre-Rx for 2 days, then Femalecs7aijenice | OSS + oral LNC 2 cas (0~55) DSS + oral Scrambled LNCs DSS + anticTNFa Ab 0.167 mg/mouse on day 0, 4 and 6 6
Slide 26: Summary of Recent Key Advances
Summary of Recent Key Advances > Successful in vivo oral delivery of LNC-Docetaxel in a melanoma tumor model * Reductions in tumor weight and volume comparable to those seen with IV docetaxel + No adverse effects on body weight or hematologic parameters. > Successful in vivo oral delivery of LNC for
Slide 27: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity ao MAT2203 potentially Global Platform IP Recent patent entitled to 12+ years base protection out to applications based on of exclusivity 2037 with 20 patents formulation wor
Slide 28: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Jerome D. Jabbour, J.D. Chief Executive Officer Chief Business Officer S<MILLENDO. *sunovion @fReliant™ James Ferguson, M.D. Chief Medical Officer Ie, AMGEN sna Astrazeneca? 2% Thomas Hoover, MBA Keith Kucinski, CPA, Chief Financial Officer PAR barr Chief D
Slide 29: Matinas Investment Thesis: Financial Summary and Near-Term Milestones
29 Matinas Investment Thesis Financial Summary pe Runway into Q3 2024 th $18.2M" in Cash, Cash Equivalents and Marketable Securities 4 ° 201 09/30/23 Ss Non-Dilutive Financing Options Ee Near-Term Milestones - Setup for Strong Start to 2024 Qu FDA Meeting to Finalize P3 Protocol Following Written Pr
Matinas BioPharma Holdings — Investor Presentation (January 2024) on 6ix